vs

Side-by-side financial comparison of Consolidated Edison (ED) and Zoetis (ZTS). Click either name above to swap in a different company.

Consolidated Edison is the larger business by last-quarter revenue ($4.0B vs $2.4B, roughly 1.7× Zoetis). Zoetis runs the higher net margin — 25.3% vs 7.5%, a 17.7% gap on every dollar of revenue. On growth, Consolidated Edison posted the faster year-over-year revenue change (8.2% vs 3.0%). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -3.7%).

Consolidated Edison, Inc., commonly known as Con Edison or ConEd, is an energy company based in New York City. It is one of the largest investor-owned energy companies in the United States, with approximately $15.26 billion in annual revenues as of 2024, and over $70 billion in assets. The company provides a wide range of energy-related products and services to its customers through its subsidiaries:Consolidated Edison Company of New York, Inc.

Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...

ED vs ZTS — Head-to-Head

Bigger by revenue
ED
ED
1.7× larger
ED
$4.0B
$2.4B
ZTS
Growing faster (revenue YoY)
ED
ED
+5.2% gap
ED
8.2%
3.0%
ZTS
Higher net margin
ZTS
ZTS
17.7% more per $
ZTS
25.3%
7.5%
ED
Faster 2-yr revenue CAGR
ZTS
ZTS
Annualised
ZTS
4.4%
-3.7%
ED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ED
ED
ZTS
ZTS
Revenue
$4.0B
$2.4B
Net Profit
$298.0M
$603.0M
Gross Margin
70.2%
Operating Margin
12.3%
31.9%
Net Margin
7.5%
25.3%
Revenue YoY
8.2%
3.0%
Net Profit YoY
-3.9%
3.8%
EPS (diluted)
$0.81
$1.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ED
ED
ZTS
ZTS
Q4 25
$4.0B
$2.4B
Q3 25
$4.6B
$2.4B
Q2 25
$3.6B
$2.5B
Q1 25
$4.9B
$2.2B
Q4 24
$3.7B
$2.3B
Q3 24
$4.2B
$2.4B
Q2 24
$3.3B
$2.4B
Q1 24
$4.3B
$2.2B
Net Profit
ED
ED
ZTS
ZTS
Q4 25
$298.0M
$603.0M
Q3 25
$688.0M
$721.0M
Q2 25
$246.0M
$718.0M
Q1 25
$791.0M
$631.0M
Q4 24
$310.0M
$581.0M
Q3 24
$588.0M
$682.0M
Q2 24
$202.0M
$624.0M
Q1 24
$720.0M
$599.0M
Gross Margin
ED
ED
ZTS
ZTS
Q4 25
70.2%
Q3 25
71.5%
Q2 25
73.6%
Q1 25
72.0%
Q4 24
69.5%
Q3 24
70.6%
Q2 24
71.7%
Q1 24
70.6%
Operating Margin
ED
ED
ZTS
ZTS
Q4 25
12.3%
31.9%
Q3 25
21.2%
37.0%
Q2 25
9.8%
36.7%
Q1 25
23.0%
36.5%
Q4 24
13.0%
31.6%
Q3 24
20.4%
36.6%
Q2 24
9.7%
33.0%
Q1 24
23.6%
34.1%
Net Margin
ED
ED
ZTS
ZTS
Q4 25
7.5%
25.3%
Q3 25
15.1%
30.0%
Q2 25
6.8%
29.2%
Q1 25
16.2%
28.4%
Q4 24
8.5%
25.1%
Q3 24
13.9%
28.6%
Q2 24
6.1%
26.4%
Q1 24
16.8%
27.4%
EPS (diluted)
ED
ED
ZTS
ZTS
Q4 25
$0.81
$1.37
Q3 25
$1.90
$1.63
Q2 25
$0.68
$1.61
Q1 25
$2.25
$1.41
Q4 24
$0.89
$1.29
Q3 24
$1.69
$1.50
Q2 24
$0.58
$1.37
Q1 24
$2.08
$1.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ED
ED
ZTS
ZTS
Cash + ST InvestmentsLiquidity on hand
$1.6B
Total DebtLower is stronger
$25.8B
Stockholders' EquityBook value
$24.2B
$3.3B
Total Assets
$74.6B
$15.5B
Debt / EquityLower = less leverage
1.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ED
ED
ZTS
ZTS
Q4 25
$1.6B
Q3 25
$181.0M
$2.1B
Q2 25
$1.5B
$1.4B
Q1 25
$360.0M
$1.7B
Q4 24
$1.3B
$2.0B
Q3 24
$93.0M
$1.7B
Q2 24
$1.5B
$1.6B
Q1 24
$169.0M
$2.0B
Total Debt
ED
ED
ZTS
ZTS
Q4 25
$25.8B
Q3 25
Q2 25
Q1 25
Q4 24
$24.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ED
ED
ZTS
ZTS
Q4 25
$24.2B
$3.3B
Q3 25
$24.2B
$5.4B
Q2 25
$23.8B
$5.0B
Q1 25
$23.8B
$4.7B
Q4 24
$22.0B
$4.8B
Q3 24
$21.9B
$5.2B
Q2 24
$21.6B
$5.0B
Q1 24
$21.6B
$5.1B
Total Assets
ED
ED
ZTS
ZTS
Q4 25
$74.6B
$15.5B
Q3 25
$71.8B
$15.2B
Q2 25
$71.5B
$14.5B
Q1 25
$70.7B
$14.1B
Q4 24
$70.6B
$14.2B
Q3 24
$68.6B
$14.4B
Q2 24
$67.9B
$14.2B
Q1 24
$66.7B
$14.3B
Debt / Equity
ED
ED
ZTS
ZTS
Q4 25
1.07×
Q3 25
Q2 25
Q1 25
Q4 24
1.13×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ED
ED
ZTS
ZTS
Operating Cash FlowLast quarter
$1.5B
$893.0M
Free Cash FlowOCF − Capex
$732.0M
FCF MarginFCF / Revenue
30.7%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
4.97×
1.48×
TTM Free Cash FlowTrailing 4 quarters
$2.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ED
ED
ZTS
ZTS
Q4 25
$1.5B
$893.0M
Q3 25
$504.0M
$938.0M
Q2 25
$2.0B
$486.0M
Q1 25
$837.0M
$587.0M
Q4 24
$1.3B
$905.0M
Q3 24
$392.0M
$951.0M
Q2 24
$1.3B
$502.0M
Q1 24
$573.0M
$595.0M
Free Cash Flow
ED
ED
ZTS
ZTS
Q4 25
$732.0M
Q3 25
$805.0M
Q2 25
$308.0M
Q1 25
$438.0M
Q4 24
$689.0M
Q3 24
$784.0M
Q2 24
$370.0M
Q1 24
$455.0M
FCF Margin
ED
ED
ZTS
ZTS
Q4 25
30.7%
Q3 25
33.5%
Q2 25
12.5%
Q1 25
19.7%
Q4 24
29.7%
Q3 24
32.8%
Q2 24
15.7%
Q1 24
20.8%
Capex Intensity
ED
ED
ZTS
ZTS
Q4 25
6.7%
Q3 25
5.5%
Q2 25
7.2%
Q1 25
6.7%
Q4 24
9.3%
Q3 24
7.0%
Q2 24
5.6%
Q1 24
6.4%
Cash Conversion
ED
ED
ZTS
ZTS
Q4 25
4.97×
1.48×
Q3 25
0.73×
1.30×
Q2 25
8.04×
0.68×
Q1 25
1.06×
0.93×
Q4 24
4.23×
1.56×
Q3 24
0.67×
1.39×
Q2 24
6.63×
0.80×
Q1 24
0.80×
0.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ED
ED

Electricity$2.9B73%
Oil And Gas Purchased$923.0M23%
Steam Plant$189.0M5%
Con Edison Transmission$1.0M0%

ZTS
ZTS

Other$1.3B56%
Livestock$234.0M10%
Pain Sedation$209.0M9%
Other Pharmaceuticals$188.0M8%
Swine$125.0M5%
Poultry$117.0M5%
Fish$81.0M3%
Other Non Pharmaceuticals$70.0M3%
Manufactured Product Other$18.0M1%
Medicated Feed Additives$12.0M1%

Related Comparisons